GAiT is an international resource to facilitate the therapeutic use of immunogenetically matched, clinical-grade new types of stem cells (iPSCs) for the benefit of patients globally. GAiT’s vision is that patients globally will have equity of access to this new generation of iPSC-derived cell therapy products.
GAiT’s mission is to enable the global human community the opportunity to benefit from the new generation of cell therapies by facilitating the development of, and access to, clinical-grade and haplotyped induced pluripotent stem cells for the manufacture of cell therapy products.
- Achieve consensus on donor selection and screening criteria and consent standards.
- Achieve global consensus on manufacturing and quality parameters and standards required to consider an iPSC line to be of clinical grade and develop an external quality assurance scheme to facilitate the development of comparability between centres.
- Gain agreement with regulators in various jurisdictions as to the acceptability of the quality standards proposed.
- Develop a database of clinical grade iPSC lines.
News & Events
The latest from GAiT
The CiRA Foundation @CiRA_F_J and
@CCRM_ca will co-chair GAiT's Industry Liaison Committee. This Committee will focus on clarifying the translation roadmap for iPSC therapeutics and how to improve efficiencies.
We pay tribute to the participants of the first iPSC Quality Assessment Round in the Stem Cell Podcast recorded today and look forward to its broadcast on in two weeks time.
The Stem Cell Podcast
Culturing knowledge in stem cell research.
Great interview of Stephen Sullivan, International Liaison Officer at the GAiT @IPSCtherapies a global initiative to support the clinical application of iPSC-based therapies, funded by @nyscf @CGTCatapult @CCRM_ca @Inserm and led by a prestigious scientific advisory board! https://twitter.com/FeyeuxMaxime/status/1397521579366625282
A poll has been sent to Industry Members' emails to schedule the first Industry Liaison Committee Meeting in the coming weeks.
#ISCT2021 Breaking News – ISCT and WHO launch CGT nomenclature standards at ISCT 2021!
Find out more: https://mailchi.mp/isctglobal/te-rmplenary-6252360
We shall be updating Participants of the iPSC Quality Assessment Round on the manuscript shortly. A professional statistician re-analysed the amalgamated dataset to fortify the paper.
GAiT is also planning its first Industry Liaisons committee meeting. Internal discussions with GAiT Director / CCRM President & CEO Michael May, to discuss schedule, materials, and format, will take place this week. GAiT will then reach out to Industry members directly.
We appreciate Participants' patience - internal reviewers of the paper were dealing with the COVID-19 response, delaying matters. As agreed, we will allow a final review before submission.
Impact of Previously Unrecognized HLA Mismatches Using Ultrahigh Resolution Typing in Unrelated Donor Hematopoietic Cell Transplantation @NeemaMayor @spellman_s, @AnthonyNolan, @CIBMTR @sophpacz
Confirming the impact of ultra-high resolution #HLA typing
Impact of Previously Unrecognized HLA Mismatches Using Ultrahigh Resolution Typing in Unrelated Donor Hematopoietic Cell Transplantation
PURPOSE Ultrahigh resolution (UHR) HLA matching is reported to result in better outcomes following unrelated donor hem...
We are getting ready to welcome you to #EFI2021
All registered delegates should have received their conference log-in details & virtual delegate bag yesterday afternoon, if you didn’t receive this email contact email@example.com
@BSHI_transplant @EFI_Office @BSHIconference